In 1995, the FDA of the United States approved lutein as a food supplement after discovering that macular degeneration in human eyes was related to the lack of lutein. There is a need to extract lutein from a large number of marigold internationally. Since 2, 3, mu of marigold has been planted in China every year and exported as lutein ester, and lutein has been produced by chemical saponification in the United States. In 21, Wu Guangyao, China took the lead in studying the enzymatic production of lutein, which was successful and patented. The lutein produced by this technology has been clinically tested in Beijing Hospital and the Third Hospital of Beijing Medical University in peking university health science center with the support of the National Natural Science Foundation, which proves the medical effect of lutein used in patients with eye diseases in China, and also proves that normal people who use computers every day need to supplement lutein. The article of the Ministry of Medicine was published in the British Journal of Nutrition in 21. Soft capsule products supplemented with 2mg lutein every day have been put into production and sales. Main achievements
Obtained a number of patents, and in 2, led a delegation to the Nile Pharmaceutical Factory in Egypt to establish a genetic engineering pharmaceutical production line, and produced granulocyte macrophage colony factor. He has cooperated with Indonesia Jinguang Group to solve the problem of rapid propagation of trees, developed pharmaceutical projects with Shandong Yuwang Industrial Company, and established a self-developed pilot production line in Beijing that meets GMP standards.